Table 2.

Population pharmacodynamic parameters derived from nonlinear mixed-effects modeling of the in vitro mefloquine susceptibility data

ParameteraAFRIMSbWellcome UnitSMRUcAll 415 strains
EC90(ng/ml)51.08 (2.20)d 49.00 (6.64)53.88 (7.49)50.43 (1.98)
95% PI for EC90(ng/ml)12.55–207.848.89–270.1513.93–208.3411.96–212.56
γ2.44 (0.06)2.47 (0.18)3.19 (0.22)2.50 (0.06)
95% PI for γ1.21–4.921.03–5.931.85–5.491.22–5.13
E max (%)102.30 (0.69)97.85 (1.59)103.96 (3.38)101.89 (0.64)
E 0 (%)−1.56 (0.46)0.36 (0.63)2.24 (0.69)−0.76 (0.35)
ωECmax 0.1060.0970.1580.110
ωEC90 0.7160.8710.6900.734
ωγ 0.3580.4470.2770.367
ςɛ (% residual error)10.858.646.7610.31
  • a ωECmax, ωEC90, and ωγ, interstrain variability for E max, EC90, and γ. PI, prediction interval.

  • b AFRIMS, U.S. Armed Forces Research Institute of Medical Sciences.

  • c SMRU, Shoklo Malaria Research Unit.

  • d Standard errors are given in parentheses.